Microparticles and their impact on intestinal immunity

Digestive Diseases

Volumn 30, Issue SUPPL. 3, 2012, Pages 47-54

  Becker, Helen M ^a   Bertschinger, Martina M ^b   Rogler, Gerhard ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Inflammasome; Interleukin 18; Microparticles

Indexed keywords

ALUMINUM SILICATE; ASBESTOS; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CRYOPYRIN; FOOD ADDITIVE; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; IRON OXIDE; KAOLIN; POTASSIUM ION; REACTIVE OXYGEN METABOLITE; TITANIUM DIOXIDE; TOOTHPASTE; URATE;

ARTICLE; CROHN DISEASE; CYTOKINE PRODUCTION; DAILY LIFE ACTIVITY; DIETARY INTAKE; DISEASE PREDISPOSITION; ENTERITIS; ENVIRONMENTAL FACTOR; FOOD; FOOD INDUSTRY; FOOD SAFETY; GASTROINTESTINAL DISEASE; HUMAN; IMMUNITY; INTESTINE; INTESTINE EPITHELIUM CELL; MACROPHAGE; NONHUMAN; PARTICLE SIZE; PEYER PATCH; PRIORITY JOURNAL; RISK FACTOR;

EID: 84872055032     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000342602     Document Type: Article

References (66)

1. Jones DE, Bevins CL: Paneth cells of the human small intestine express an antimicrobial peptide gene. J Biol Chem 1992;267:23216-23225.
2. O'Neil DA, Porter EM, Elewaut D, et al: Expression and regulation of the human betadefensins hBD-1 and hBD-2 in intestinal epithelium. J Immunol 1999;163:6718-6724.
3. Franke A, McGovern DP, Barrett JC, et al: Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010;42:1118-1125.
4. Villani AC, Lemire M, Fortin G, et al: Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat Genet 2009;41:71-76.
5. Mariathasan S, Weiss DS, Newton K, et al: Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006;440:228-232. (Pubitemid 43372102)
6. Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J: Innate immune activation through NALP3 inflammasome sensing of asbestos and silica. Science 2008;320:674-677. (Pubitemid 351928351)
7. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237-241. (Pubitemid 43372104)
8. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J: NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004;20:319-325. (Pubitemid 38388233)
9. Roberts RL, Topless RK, Phipps-Green AJ, Gearry RB, Barclay ML, Merriman TR: Evidence of interaction of CARD8 rs2043211 with NALP3 rs35829419 in Crohn's disease. Genes Immun 2010;11:351-356.
10. Schoultz I, Verma D, Halfvarsson J, et al: Combined polymorphisms in genes encoding the inflammasome components NALP3 and CARD8 confer susceptibility to Crohn's disease in Swedish men. Am J Gastroenterol 2009;104:1180-1188.
11. Kastbom A, Verma D, Eriksson P, Skogh T, Wingren G, Soderkvist P: Genetic variation in proteins of the cryopyrin inflammasome influences susceptibility and severity of rheumatoid arthritis (the Swedish TIRA project). Rheumatology (Oxford) 2008;47:415-417.
12. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD: Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001;29:301-305. (Pubitemid 33096455)
13. Feldmann J, Prieur AM, Quartier P, et al: Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet 2002;71:198-203. (Pubitemid 34734724)
14. Martinon F, Mayor A, Tschopp J: The inflammasomes: guardians of the body. Annu Rev Immunol 2009;27:229-265.
15. Tschopp J, Schroder K: NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production? Nat Rev Immunol 2010;10:210-215.
16. Kanneganti TD, Body-Malapel M, Amer A, et al: Critical role for cryopyrin/NALP3 in activation of caspase-1 in response to viral infection and double-stranded RNA. J Biol Chem 2006;281:36560-36568. (Pubitemid 46042123)
17. Allen IC, Scull MA, Moore CB, et al: The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity 2009;30:556-565.
18. Muruve DA, Petrilli V, Zaiss AK, et al: The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 2008;452:103-107. (Pubitemid 351355095)
19. Munoz-Planillo R, Franchi L, Miller LS, Nunez G: A critical role for hemolysins and bacterial lipoproteins in Staphylococcus aureus-induced activation of the NLRP3 inflammasome. J Immunol 2009;183:3942-3948.
20. Warren SE, Mao DP, Rodriguez AE, Miao EA, Aderem A: Multiple Nod-like receptors activate caspase-1 during Listeria monocytogenes infection. J Immunol 2008;180:7558-7564.
21. Lamkanfi M, Malireddi RK, Kanneganti TD: Fungal zymosan and mannan activate the cryopyrin inflammasome. J Biol Chem 2009;284:20574-20581.
22. Joly S, Ma N, Sadler JJ, Soll DR, Cassel SL, Sutterwala FS: Cutting edge: Candida albicans hyphae formation triggers activation of the NLRP3 inflammasome. J Immunol 2009;183:3578-3581.
23. Said-Sadier N, Padilla E, Langsley G, Ojcius DM: Aspergillus fumigatus stimulates the NLRP3 inflammasome through a pathway requiring ROS production and the Syk tyrosine kinase. PLoS ONE 2010;5:e10008.
24. Kanneganti TD, Ozoren N, Body-Malapel M, et al: Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/NALP3. Nature 2006;440:233-236. (Pubitemid 43372103)
25. Gurcel L, Abrami L, Girardin S, Tschopp J, van der Goot FG: Caspase-1 activation of lipid metabolic pathways in response to bacterial pore-forming toxins promotes cell survival. Cell 2006;126:1135-1145. (Pubitemid 44380297)
26. Pelegrin P, Surprenant A: Pannexin-1 couples to maitotoxin-and nigericin-induced interleukin-1beta release through a dye uptake-independent pathway. J Biol Chem 2007;282:2386-2394. (Pubitemid 47076789)
27. Dostert C, Guarda G, Romero JF, et al: Mala rial hemozoi n is an NALP3 inf lammasome activating danger signal. PLoS ONE 2009;4:e6510.
28. Yamasaki K, Muto J, Taylor K R, et al: NLRP3/cryopyrin is necessary for interleukin-1beta (IL-1beta) release in response to hyaluronan, an endogenous trigger of inflammation in response to injury. J Biol Chem 2009;284:12762-12771.
29. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J: Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010;11:136-140.
30. Halle A, Hornung V, Petzold GC, et al: The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 2008;9:857-865.
31. Hornung V, Bauernfeind F, Halle A, et al: Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosoma l destabilization. Nat Immunol 2008;9:847-856.
32. Cassel SL, Eisenbarth SC, Iyer SS, et al: The NALP3 inflammasome is essential for the development of silicosis. Proc Natl Acad Sci USA 2008;105:9035-9040.
33. Duewell P, Kono H, Rayner KJ, et al: NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010;464:1357-1361.
34. Thompson NP, Driscoll R, Pounder RE, Wakefield AJ: Genetics versus environment in inflammatory bowel disease: results of a British twin study. BMJ 1996;312:95-96. (Pubitemid 26015449)
35. Tysk C, Lindberg E, Jarnerot G, Floderus-Myrhed B: Ulcerative colitis and Crohn's disease in an unselec ted popu lat ion of monoz ygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 1988;29:990-996.
36. Orholm M, Binder V, Sorensen TI, Rasmussen LP, Kyvik KO: Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. Scand J Gastroenterol 2000;35:1075-1081.
37. Jess T, Riis L, Jespersgaard C, et al: Disease concordance, zygosity, and NOD2/CARD15 status: follow-up of a population-based cohort of Danish twins with inflammatory bowel disease. Am J Gastroenterol 2005;100:2486-2492.
38. Hanauer SB: Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006;12(suppl 1):S3-S9. (Pubitemid 43068428)
39. Loftus EV Jr: Clinical epidemiology of inflammator y bowel diseas e: Incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-1517. (Pubitemid 38649869)
40. European Parliament C: On colours for use in foodstuffs. 1994:13-29.
41. Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Cogliano V: Carcinogenicity of carbon black, titanium dioxide, and talc. Lancet Oncol 2006;7:295-296.
42. Lomer MC, Thompson RP, Powell JJ: Fine and ultrafine particles of the diet: influence on the mucosal immune response and association with Crohn's disease. Proc Nutr Soc 2002;61:123-130. (Pubitemid 34173020)
43. European Food Safety Authority: Opinion of the Scientific Panel on Food Additives, Flavourings, Processing Aids and Materials in Contact with Food on a request from the commission related to the safety-in-use of rutile titanium dioxide as an alternative to the presently permitted anatase form. EFSA J 2004;163:1-12.
44. Lomer MC, Hutchinson C, Volkert S, et al: Dietary sources of inorganic microparticles and their intake in healthy subjects and patients with Crohn's disease. Br J Nutr 2004;92:947-955. (Pubitemid 40028856)
45. Powell JJ, Thoree V, Pele LC: Dietary microparticles and their impact on tolerance and immune responsiveness of the gastrointestinal tract. Br J Nutr 2007;98(suppl 1):S59-S63. (Pubitemid 47543479)
46. Shepherd NA, Crocker PR, Smith AP, Levison DA: Exogenous pigment in Peyer's patches. Hum Pathol 1987;18:50-54. (Pubitemid 17026158)
47. Powell JJ, Ainley CC, Harvey RS, et al: Characterisation of inorganic microparticles in pigment cells of human gut-associated lymphoid tissue. Gut 1996;38:390-395. (Pubitemid 26075535)
48. Urbanski SJ, Arsenault AL, Green FH, Haber G: Pigment resembling atmospheric dust in Peyer's patches. Mod Pathol 1989;2:222-226.
49. Lomer MC, Thompson RP, Powell JJ: Fine and ultrafine particles of the diet: influence on the mucosal immune response and association with Crohn's disease. Proc Nutr Soc 2002;61:123-130. (Pubitemid 34173020)
50. Jani PU, McCarthy DE, Florence AT: Titanium dioxide (rutile) particle uptake from the rat GI tract and translocation to systemic organs after oral administration. Int J Pharma 1994;105:157-168. (Pubitemid 24097168)
51. Ramsden CS, Smith TJ, Shaw BJ, Handy RD: Dietary exposure to titanium dioxide nanoparticles in rainbow trout, (Oncorhynchus mykiss): no effect on growth, but subtle biochemical disturbances in the brain. Ecotoxicology 2009;18:939-951.
52. Bockmann J, Lahl H, Eckert T, Unterhalt B: Blood titanium levels before and after oral administration titanium dioxide. Pharmazie 2000;55:140-143. (Pubitemid 30243268)
53. Best WR, Becktel JM, Singleton JW, Kern F Jr: Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-444.
54. Lomer MC, Grainger SL, Ede R, et al: Lack of efficacy of a reduced microparticle diet in a multi-centred trial of patients with active Crohn's disease. Eur J Gastroenterol Hepatol 2005;17:377-384. (Pubitemid 40411227)
55. Winter M, Beer HD, Hornung V, Kramer U, Schins RP, Forster I: Activation of the inflammasome by amorphous silica and TiO (2) nanoparticles in murine dendritic cells. Nanotoxicology 2011;5:326-340.
56. Yazdi AS, Guarda G, Riteau N, et al: Nanoparticles activate the NLR pyrin domain containing 3 (NLRP3) inflammasome and cause pu lmonar y inf lammation through release of IL-1alpha and IL-1beta. Proc Natl Acad Sci USA 2010;107:19449-19454.
57. Franchi L, Eigenbrod T, Nunez G: Cutting edge: TNF-alpha mediates sensitization to ATP and silica via the NLRP3 inflammasome in the absence of microbial stimulation. J Immunol 2009;183:792-796.
58. Chen GY, Nunez G: Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 2010;10:826-837.
59. Petrilli V, Papin S, Dostert C, Mayor A, Martinon F, Tschopp J: Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell death and differentiation 2007;14:1583-1589. (Pubitemid 47278844)
60. Windelborn JA, Lipton P: Lysosomal release of cathepsins causes ischemic damage in the rat hippocampal slice and depends on NMDA-mediated calcium influx, arachidonic acid metabolism, and free radical production. J Neurochem 2008;106:56-69. (Pubitemid 351840201)
61. Li Z, Berk M, McIntyre TM, Gores GJ, Feldstein AE: The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology 2008;47:1495-1503. (Pubitemid 351702733)
62. Monteleone G, Trapasso F, Parrello T, et al: Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol 1999;163:143-147. (Pubitemid 29295835)
63. Pizarro TT, Michie MH, Bentz M, et al: IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J Immunol 1999;162:6829-6835. (Pubitemid 29309411)
64. Moyes SM, Smyth SH, Shipman A, Long S, Morris JF, Carr KE: Parameters influencing intestinal epithelial permeability and microparticle uptake in vitro. Int J Pharm 2007;337:133-141. (Pubitemid 46766617)
65. Koeneman BA, Zhang Y, Westerhoff P, Chen Y, Crittenden JC, Capco DG: Toxicity and cellular responses of intestinal cells exposed to titanium dioxide. Cell Biol Toxicol; 26:225-238.
66. Tschopp J, Martinon F, Burns K: NALPs: a novel protein family involved in inflammation. Nat Rev Mol Cell Biol 2003;4:95-104. (Pubitemid 36172693)